Rimonabant: From RIO to Ban
- PMID: 21773005
- PMCID: PMC3136184
- DOI: 10.1155/2011/432607
Rimonabant: From RIO to Ban
Abstract
Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century. The CB1 receptor antagonist Rimonabant entered the European mass market on the back of several trials showing weight loss benefits alongside improvements in numerous other elements of the metabolic syndrome. However, the drug was quickly withdrawn due to the emergence of significant side effects-notably severe mood disorders. This paper provides a brief overview of the Rimonabant story and places the recent spate of FDA rejections of other centrally acting weight loss drugs entering Phase 3 trials in this context.
References
-
- Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–65. - PubMed
-
- De Vries TJ, Homberg JR, Binnekade R, Raasø H, Schoffelmeer ANM. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology. 2003;168(1-2):164–169. - PubMed
-
- Thanos PK, Dimitrakakis ES, Rice O, Gifford A, Volkow ND. Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. Behavioural Brain Research. 2005;164(2):206–213. - PubMed
-
- Navarro M, Hernández E, Muñoz RM, et al. Acute administration of the CB cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. NeuroReport. 1997;8(2):491–496. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
